Pop a pill or give myself a shot? Patient perspectives of disease-modifying anti-rheumatic drug choice for rheumatoid arthritis

Singh, Jasvinder A.; Tornberg, Haley; Goodman, Susan M.

doi:10.1016/j.jbspin.2020.07.002

Cited by 3 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of characteristics of these studies, 9 studies are qualitative studies while 25 are quantitative, among which 16 studies used a conjoint analysis design (including discrete choice experiment). Except for two studies with a general population23 26 and seven studies with mixed patients (at least two disease types among RA, AS, axSpA, psoriasis and PsA),27 29 33 35 38 48 52 16 studies were carried out in patients with RA,5 20–22 28 30 34 36 37 41–43 47 49–51 eight in patients with psoriasis24 31 32 40 44–46 53 and one in patients with axSpA 39. Thirty-one (91%) studies were conducted in Western countries, while the others were conducted in Asia (one from China30 and two from Japan36 46).…”

Section: Resultsmentioning

confidence: 99%

“…Overview Two thousand two hundred and sixty-one studies were searched out of four databases, and 15 studies were added from the manual research of a systematic review. 19 After removing 466 duplications, 1713 irrelevant studies during abstract screening, and 63 other ineligible studies by inclusion/exclusion criteria, 34 papers were included and assessed for content analysis (initiation: N=4 [20][21][22][23] ; preference: N=8 [24][25][26][27][28][29][30][31] ; discontinuation: N=8 [32][33][34][35][36][37][38][39] ; initiation/preference: N=13 [40][41][42][43][44][45][46][47][48][49][50][51][52] ; initiation/discontinuation: N=1 53 ). The study selection flow diagram is shown in online supplemental figure 1.…”

Section: Systematic Review Of Global Evidencementioning

confidence: 99%

See 1 more Smart Citation

Factors influencing choice of b/ts DMARDs in managing inflammatory arthritis from a patient perspective: a systematic review of global evidence and a patient-based survey from Hong Kong

Li,

Lau,

Peng

et al. 2023

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo investigate factors concerning patients regarding biological/target synthetic disease-modifying antirheumatic drugs (b/ts DMARDs) in treating inflammatory arthritis (IA).DesignThis study consists of a systematic review and a cross-sectional survey in Hong Kong. A systematic review of literature following Preferred Reporting Items for Systematic Reviews and Meta-Analyses was conducted on PubMed, Web of Science, Cochrane and Embase between 1 January 2000 and 1 January 2022. Content analysis was conducted to summarise factors grouped by four themes—social aspects (SA), clinical aspects (CA), medicine characteristics (MC) and financial aspects (FA) in the decision-making process. One cross-sectional survey among Hong Kong patients with IA was conducted to add to global evidence.SettingA systematic review of global evidence and a patient-based survey in Hong Kong to complement scarce evidence in Asia regions.ResultsThe systematic review resulted in 34 studies. The four themes were presented in descending order consistently but varied with frequency throughout decision-making processes. During decision-making involving medication initiation, preference and discontinuation, MC (reported frequency: 83%, 86%, 78%), SA (56%, 43%, 78%) and FA (39%, 33%, 56%) were the three most frequently reported factors, whereas CA was less studied. Local survey also revealed that MC factors such as treatment efficacy and the probability of severe adverse events, and SA factors such as the availability of government or charity subsidy, influenced patients’ initiation and preference for b/ts DMARDs. Meanwhile, self-estimated improvement in disease conditions (SA), drug side effects (MC) and drug costs (FA) were associated with treatment discontinuation.ConclusionsGlobal and local evidence consistently indicate that MC and SA are important considerations in patients’ decisions regarding novel DMARDs. Health policies that reduce patients’ financial burden and enhances healthcare professionals’ engagement in decision-making and treatment delivery should be in place with an efficient healthcare system for managing IA optimistically.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Systematic Review Of Global Evidencementioning

confidence: 99%

Factors influencing choice of b/ts DMARDs in managing inflammatory arthritis from a patient perspective: a systematic review of global evidence and a patient-based survey from Hong Kong

Li,

Lau,

Peng

et al. 2023

BMJ Open

View full text Add to dashboard Cite

show abstract

“…The lack of tweets related to treatment adherence is noteworthy and is also reflected in the scientific literature. While there are studies assessing adherence in patients with conditions such as hypertension, diabetes, and epilepsy [45], there is a dearth of robust data on adherence in autoimmune diseases [46,47]. This is similarly observed in studies on the treatment of mental illness, where tweets related to adherence are infrequent or absent [35,48].…”

Section: Discussionmentioning

confidence: 99%

Using Twitter Data Analysis to Understand the Perceptions, Beliefs, and Attitudes about Pharmacotherapy Used in Rheumatology: An Observational Study

et al. 2023

View full text Add to dashboard Cite

Twitter has become an important platform for disseminating information about rheumatology drugs by patients, health professionals, institutions, and other users. The aim of this study was to analyze tweets related to 16 drugs used in rheumatology, including their volume, content, and type of user (patients, patients’ relatives, health professionals, health institutions, pharmaceutical industry, general press, scientific journals and patients’ associations), and to detect inappropriate medical content. A total of 8829 original tweets were obtained, with a random sample of 25% of the total number of tweets for each drug (at least 100 tweets) analyzed. Methotrexate (MTX) accounted for a quarter of all tweets, and there were significant differences in the proportion of tweets issued according to the type of user. Patients and their relatives mainly tweeted about MTX, while professionals, institutions, and patient associations posted more about TNF inhibitors. In contrast, the pharmaceutical industry focused on IL-17 inhibitors. Medical content prevailed in all drugs except anti-CD20 and IL-1 inhibitors and the most discussed medical topic was efficacy, followed by posology and adverse effects. Inappropriate or fake content was found to be very low. In conclusion, the majority of the tweets were about MTX, which is a first-line treatment for several diseases. The distribution of medical content varied according to the type of user. In contrast to other studies, the amount of medically inappropriate content was very low.

show abstract

“…Despite the widespread use of MTX, little is known about patients' attitudes towards MTX therapy for RA, particularly the barriers and enablers toward use in a parenteral form. Prior qualitative research has focused on the patients' perception toward injectable bDMARDs (29)(30)(31)(32). Storage issues, needle problems, and difficulties in administration have been identified as barriers to the use of injectable bDMARDs in a recent qualitative study (30).…”

Section: Introductionmentioning

confidence: 99%

Barriers and Enablers in the Use of Parenteral Methotrexate in Rheumatoid Arthritis Patients: A Scoping Review

Tan

Reeve

Fraser

et al. 2023

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveMethotrexate (MTX) is effective in controlling disease activity in rheumatoid arthritis (RA). Parenteral MTX may have benefits over oral MTX, but it is rarely used in practice. To better understand this low usage rate, it is necessary to explore the barriers and enablers of therapy from the perspective of RA patients. The objectives of this scoping review were to describe RA patients’ perspectives on the barriers and enablers in the use of parenteral MTX and to identify the research gaps in this field.MethodsThe search was performed in Medline, Embase, Scopus, and Cochrane Library from inception to May 2021. Data synthesis was conducted using the Theoretical Framework of Acceptability. This scoping review included any type of study that explored the use of parenteral MTX by adult RA patients from the patients’ perspective, written in English.ResultsFifteen studies were included; findings related to the constructs “affective attitude,” “burden,” “intervention coherence,” and “self‐efficacy” were explored the most, while some were rarely (“opportunity cost” and “perceived effectiveness”) or not (“ethicality”) reported. RA patients were generally satisfied with MTX injections (“affective attitude”). From the burden construct, the requirement for dexterity for administering MTX by injection was considered a barrier, whereas the lack of significant pain from MTX injection was considered an enabler.ConclusionThe findings suggested that patients generally preferred parenteral MTX formulations with attributes that facilitate self‐administration. However, much of the identified research focused on prefilled pen devices, and significant gaps were identified, such as a lack of qualitative research.image

show abstract

Pop a pill or give myself a shot? Patient perspectives of disease-modifying anti-rheumatic drug choice for rheumatoid arthritis

Cited by 3 publications

References 33 publications

Factors influencing choice of b/ts DMARDs in managing inflammatory arthritis from a patient perspective: a systematic review of global evidence and a patient-based survey from Hong Kong

Factors influencing choice of b/ts DMARDs in managing inflammatory arthritis from a patient perspective: a systematic review of global evidence and a patient-based survey from Hong Kong

Using Twitter Data Analysis to Understand the Perceptions, Beliefs, and Attitudes about Pharmacotherapy Used in Rheumatology: An Observational Study

Barriers and Enablers in the Use of Parenteral Methotrexate in Rheumatoid Arthritis Patients: A Scoping Review

Contact Info

Product

Resources

About